vcvibes

Jls

Emerging manager

Built from this firm's Form D filings. The firm files no SEC adviser report.

HQ
NY

Jls is a venture firm that finances and helps build companies turning breakthroughs in neuroscience, technology, and data into outcomes for patients and value for strategic acquirers. Lindsay Hoover and Simeon Schnapper are listed as managing partners, with Jeffrey Siegel as partner and investor relations contact. The firm's portfolio includes ProNovo Therapeutics, which develops precision therapeutics for neuropsychiatric disorders such as Major Depressive Disorder and Schizophrenia.

01 · Says / Does

TagSaysDoes
StagesNot statedNot enough dated deals
SectorsHealthtech, BiotechNot enough dated deals
RegionsNot statedNot enough dated deals

Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.

02 · Fund history

FundYearSizeStatus
JLS Fund II LP

Finances and helps build companies that translate breakthroughs in neuroscience, technology, and data into patient outcomes and value for strategic acquirers. Portfolio spans psychedelic-assisted therapy, neuropsychiatric therapeutics, and psychiatric biotech. Inferred from the firm's website

2023$13.03M (Form D)Open, writing first checks
JLS Fund 1 LP2021$5.26M to $50M (Form D)Follow-ons only

03 · People across funds

04 · Recent deals

No dated deals found yet.

05 · Latest from the firm

No news from the firm's website yet.

06 · Sources

  1. https://www.jls.fund
  2. https://www.jls.fund/
  3. https://www.jls.fund/team

Fund dates and sizes are from SEC Form D filings.

Last verified: Oct 28, 2026